These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 23260229)
1. Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Hodge JM; Wang Y; Berk M; Collier FM; Fernandes TJ; Constable MJ; Pasco JA; Dodd S; Nicholson GC; Kennedy RL; Williams LJ Biol Psychiatry; 2013 Jul; 74(1):32-9. PubMed ID: 23260229 [TBL] [Abstract][Full Text] [Related]
2. Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats. Oosting RS; Chan JS; Olivier B; Banerjee P; Choi YK; Tarazi F Psychopharmacology (Berl); 2016 Mar; 233(6):1025-34. PubMed ID: 26758283 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Baumann P Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657 [TBL] [Abstract][Full Text] [Related]
4. Serotonin and fluoxetine modulate bone cell function in vitro. Gustafsson BI; Thommesen L; Stunes AK; Tommeras K; Westbroek I; Waldum HL; Slørdahl K; Tamburstuen MV; Reseland JE; Syversen U J Cell Biochem; 2006 May; 98(1):139-51. PubMed ID: 16408289 [TBL] [Abstract][Full Text] [Related]
5. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Preskorn SH Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Sánchez C; Hyttel J Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421 [TBL] [Abstract][Full Text] [Related]
8. Utility of organotypic raphe slice cultures to investigate the effects of sustained exposure to selective 5-HT reuptake inhibitors on 5-HT release. Nagayasu K; Yatani Y; Kitaichi M; Kitagawa Y; Shirakawa H; Nakagawa T; Kaneko S Br J Pharmacol; 2010 Dec; 161(7):1527-41. PubMed ID: 20698856 [TBL] [Abstract][Full Text] [Related]
10. The pharmacogenetics of the selective serotonin reuptake inhibitors. Brøsen K Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052 [TBL] [Abstract][Full Text] [Related]
11. Citalopram and sertraline exposure compromises embryonic bone development. Fraher D; Hodge JM; Collier FM; McMillan JS; Kennedy RL; Ellis M; Nicholson GC; Walder K; Dodd S; Berk M; Pasco JA; Williams LJ; Gibert Y Mol Psychiatry; 2016 May; 21(5):656-64. PubMed ID: 26347317 [TBL] [Abstract][Full Text] [Related]
12. Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect. Ortuño MJ; Robinson ST; Subramanyam P; Paone R; Huang YY; Guo XE; Colecraft HM; Mann JJ; Ducy P Nat Med; 2016 Oct; 22(10):1170-1179. PubMed ID: 27595322 [TBL] [Abstract][Full Text] [Related]
13. Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths. Cao TXD; Filliter C; Montastruc F; Yu OHY; Fergusson E; Rej S; Azoulay L; Renoux C J Affect Disord; 2022 Dec; 318():231-237. PubMed ID: 36084758 [TBL] [Abstract][Full Text] [Related]